Table 2.
Cancer-treating nanomedicines already approved or being applied in the clinical trials.
| Brand | Delivery System | Indications | Company | Current Status |
|---|---|---|---|---|
| NanoTherm® | Iron oxide nanoparticle | Local treatment of glioblastomas | MagForce AG | Approved in Germany |
| Aurimmune® | Colloidal gold-bound recombinant human tumor necrosis factor | Pancreatic cancer | CytImmune Sciences | Phase 2 clinical trial |
| Doxil®(US) [Caelyx®(Europe)] | PEGylated liposome doxorubicin | Ovarian/BC | Orthobiotech, Schering-Plough | FDA approved |
| Abraxane® | Albumin-bound Paclitaxel nanoparticles | Various cancer therapy | Abraxis Bioscience | FDA approved |
| Nab paclitaxel in combination with gemcitabine | Metastatic pancreatic cancer | Celgene | FDA approved | |
| Myocet® | Non-PEGylated liposome of Doxorubicin | BC therapy | Elan Pharmaceuticals/Sopherion Therapeutics | Approved in Europe and Canada |
| DaunoXome® | Liposome-encapsulated Daunorubicin | Advanced HIV-associated Kaposi sarcoma | Gilead Science | FDA approved |
| DepoCyt® | Liposomal Cytarabine | Lymphomatous meningitis | Pacira Pharms Inc. | FDA approved |
| Oncaspar® | PEGylated L-asparaginase | Acute Lymphocytic Leukemia | Sigma Tau | FDA approved |
| Onco-TCS® | Liposomal Vincristine | Non-Hodgkin Lymphoma | Inex | Phase 1/2 clinical trial |
| LEP-ETU® | Liposomal Paclitaxel | Ovarian/breast/lung cancers | Neopharma | Phase 1/2 clinical trial |
| Aroplatin® | Liposomal Cisplatin analog | Colorectal cancer | Antigenics, Inc. | Phase 1/2 clinical trial |
| OSI-211 | Liposomal Lurtotecan | Lung cancer/recurrent ovarian cancer | OSI | Phase 2 clinical trial |
| SPI-77 | PEGylated liposomal Cisplatin | Head and Neck cancer/Lung cancer | Alza | Phase 3 clinical trial |
| EndoTAG-1 | Paclitaxel embedded in liposomal membranes | BC/Pancreatic cancer | Medigene/SynCore Biotechnology | Phase 2 clinical trial |
| Marqibo® | Vincristine | Philadelphia chromosome-negative lymphoblastic leukemia | Talon Therapeutics | FDA approved |
| ThemoDox® | Doxorubicin | Hepatocellular carcinoma | Celsion Corporation | Phase 3 clinical trial |
| Atragen® | Liposomal all trans-retinoic acid | Acute promyelocytic leukemia | Aronex Pharmaceuticals | Phase 2 clinical trial |
| Lipoplatin® | Liposomal Cisplatin | Pancreatic/Head and Neck/BC | Regulon | Phase 3 clinical trial |
| Aurimmune® (CYT-6091) | TNF-α bound to colloidal gold nanoparticles | Head and Neck cancer | Cytimmune Sciences | Phase 2 clinical trial |
| Auroshell® | Gold nanoshell | Thermally destroy the tumor tissue | Nanospectra Bioscience | Phase 1 clinical trial |
| Genexol-PM® | Polymeric micelle loaded with paclitaxel | BC/small cell lung cancer | Samyang | Approved in Europe and Korea |
| Paclical® | Paclitaxel micelles | Ovarian cancer | Oasmia Pharmaceutical AB | Phase 3 clinical trial |
| Narekt-102 | PEGylated liposome loaded with Irinotecan | Breast/Colorectal cancer | Nektar Therapeutics | Phase 3 clinical trial |
| NKTR-105 | PEG-Docetaxel conjugate | Solid tumors | Nektar Therapeutics | Phase 1 clinical trial |